ATE535231T1 - Verfahren zur herstellung von poly-iclc und seine verwendung - Google Patents

Verfahren zur herstellung von poly-iclc und seine verwendung

Info

Publication number
ATE535231T1
ATE535231T1 AT03819324T AT03819324T ATE535231T1 AT E535231 T1 ATE535231 T1 AT E535231T1 AT 03819324 T AT03819324 T AT 03819324T AT 03819324 T AT03819324 T AT 03819324T AT E535231 T1 ATE535231 T1 AT E535231T1
Authority
AT
Austria
Prior art keywords
iclc
poly
producing poly
neoplastic
effective dose
Prior art date
Application number
AT03819324T
Other languages
English (en)
Inventor
Andres Salazar
Original Assignee
Oncovir Inc
Andres Salazar
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncovir Inc, Andres Salazar filed Critical Oncovir Inc
Application granted granted Critical
Publication of ATE535231T1 publication Critical patent/ATE535231T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT03819324T 2002-07-03 2003-07-01 Verfahren zur herstellung von poly-iclc und seine verwendung ATE535231T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39371302P 2002-07-03 2002-07-03
PCT/US2003/020828 WO2005102278A1 (en) 2002-07-03 2003-07-01 Method for preparation of poly-iclc and uses thereof

Publications (1)

Publication Number Publication Date
ATE535231T1 true ATE535231T1 (de) 2011-12-15

Family

ID=35196710

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03819324T ATE535231T1 (de) 2002-07-03 2003-07-01 Verfahren zur herstellung von poly-iclc und seine verwendung

Country Status (6)

Country Link
US (1) US7439349B2 (de)
EP (1) EP1778186B1 (de)
AT (1) ATE535231T1 (de)
AU (1) AU2003248791A1 (de)
ES (1) ES2378150T3 (de)
WO (1) WO2005102278A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2592922A1 (en) * 2004-12-29 2006-07-06 Mannkind Corporation Methods to trigger, maintain and manipulate immune responses by targeted administration of biological response modifiers into lymphoid organs
EP1723971A1 (de) * 2005-05-20 2006-11-22 Immunoclin Limited Methoden und Zusammensetzungen zur Behandlung von viralen Erkrankungen
CA2668020A1 (en) * 2006-11-03 2008-05-08 Her Majesty The Queen, In Right Of Canada, As Represented By The Ministe R Of National Defence Liposome encapsulated poly-iclc method to prophylactically treat an avian influenza viral infection
CN101687900A (zh) * 2007-03-07 2010-03-31 恩文塔生物制药公司 双链锁核酸组合物
US20090088401A1 (en) * 2007-09-27 2009-04-02 Andres Salazar In-situ cancer autovaccination with intratumoral stabilized dsRNA viral mimic
EP2275085A1 (de) * 2009-07-07 2011-01-19 University of Rostock Biologisch abbaubares Copolymer zur Freisetzung von Nukleinsäurematerial in Zellen
US8569255B2 (en) 2011-02-02 2013-10-29 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of National Defence Post-exposure therapy of influenza A infections
EP2744502B1 (de) * 2011-08-17 2016-03-30 Oregon Health & Science University Verfahren zur prävention von hypoxischen läsionen
WO2014210540A1 (en) 2013-06-28 2014-12-31 Baylor Research Institute Dendritic cell asgpr targeting immunotherapeutics for multiple sclerosis
WO2015035128A1 (en) * 2013-09-06 2015-03-12 Vaxin Inc. Methods and compositions for viral vectored vaccines
PT3319587T (pt) 2015-11-17 2019-11-20 Bioncotech Therapeutics S L Nova composição farmacêutica que compreende partículas compreendendo um complexo de um polirribonuleótido de cadeia dupla e uma polialquilenoimina
JP2020520368A (ja) 2017-05-17 2020-07-09 ビオンコテック セラピューティクス エセ．エレ 二本鎖ポリリボヌクレオチドとポリアルキレンイミンとの複合体を含む粒子を含む新規な医薬組成物
CA3145773A1 (en) 2019-07-03 2021-01-07 Aim Immunotech Inc. Compositions and methods useful for ebola virus infection
AU2021211012A1 (en) 2020-01-24 2022-08-25 Aim Immunotech Inc. Methods, compositions, and vaccines for treating a virus infection
EP3999645A1 (de) 2020-09-21 2022-05-25 Aim Immunotech Inc. Zusammensetzungen und verfahren zur behandlung von krebs
WO2022235984A1 (en) 2021-05-05 2022-11-10 Aim Immunotech Inc. Methods and compositions for treating neuroinflammation
US20250090570A1 (en) * 2021-06-21 2025-03-20 Oncovir, Inc. Method for Prophylaxis and Attenuation of COVID19 and other Inflammatory Microbial Acute Respiratory Disease Syndromes through Modulation of Innate and Adaptive Immunity with Poly ICLC
UY39877A (es) * 2021-07-30 2023-02-28 Esteban Celis Actividad biológica multidimensional optimizada de poli-iclc con tamaño y formulación de componentes
WO2023023676A1 (en) 2021-08-20 2023-02-23 Aim Immunotech Inc. Compositions and methods for treating post-covid conditions of fatigue
WO2023049904A1 (en) 2021-09-24 2023-03-30 Aim Immunotech Inc. Compositions and methods for enhancing and expanding infection induced immunity
CN120789234B (zh) * 2025-07-21 2026-04-14 神州智康(北京)生物科技有限公司 一种增强细胞免疫的复合佐剂及其制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1364987A (en) * 1971-06-19 1974-08-29 Merck Patent Gmbh Biologically active two component complexes
US4024241A (en) * 1974-09-27 1977-05-17 The United States Of America As Represented By The Secretary Of Health, Education And Welfare Nuclease-resistant hydrophilic complex of polyriboinosinic-polyribocytidylic acid
US4349538A (en) * 1979-12-07 1982-09-14 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nuclease-resistant hydrophilic complex of polyriboinosinic-polyribocytidylic acid
US4388306A (en) * 1980-06-04 1983-06-14 Merck & Co., Inc. Pharmaceutical composition comprising modified polyriboinosinic-polyribocytidylic acid, for induction of interferon in primates
US4389395A (en) * 1981-01-09 1983-06-21 Lerner A Martin Low molecular weight complex of polyriboinosinic-polyribocytidylic acid and method of inducing interferon
JPS5993097A (ja) * 1982-11-16 1984-05-29 Yamasa Shoyu Co Ltd ポリヌクレオチド複合体
CA2203843C (en) * 1997-04-28 2013-07-23 Her Majesty The Queen, In Right Of Canada, As Represented By The Ministe R Of National Defence Liposome-encapsulated poly iclc
AT410173B (de) * 2000-06-08 2003-02-25 Cistem Biotechnologies Gmbh Antigene zusammensetzung

Also Published As

Publication number Publication date
WO2005102278A1 (en) 2005-11-03
US7439349B2 (en) 2008-10-21
EP1778186A4 (de) 2007-05-09
US20040005998A1 (en) 2004-01-08
EP1778186B1 (de) 2011-11-30
ES2378150T3 (es) 2012-04-09
AU2003248791A1 (en) 2005-11-09
EP1778186A1 (de) 2007-05-02

Similar Documents

Publication Publication Date Title
EP1778186A4 (de) Verfahren zur herstellung von poly-iclc und seine verwendung
DE60319865D1 (de) Substituierte amin-derivate und deren verwendung zur behandlung von angionese-bedingten erkrankungen
DE602004031134D1 (de) Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
UA81676C2 (ru) Композиция для лечения инфекций у крупного рогатого скота и свиней
ATE517632T1 (de) Niedrigdosierte verfahren zur behandlung von erkrankungen, bei denen tnf-alpha-aktivität schädlich ist
DE60327622D1 (de) Kombinierte antitachykardie - schrittmacher und hochspannungstherapie zur behandlung von ventrikulären arrhythmien
DE60212964D1 (de) Zusammensetzungen zur behandlung von tierischen krankheiten und syndromen mit transferfaktor
DE602004022061D1 (de) Verwendung von modifizierten cyclosporinen zur behandlung von hcv-erkrankungen
ATE540129T1 (de) Target zur therapie kognitiver behinderungen
DE60329516D1 (de) Antiallergisches mittel, seine verwendung zur verringerung von allergien und verfahren zur verringerung von allergien
EA200300929A1 (ru) Новые лекарственные композиции на основе антихолинергических средств и ингибиторов pde-iv
ATE415962T1 (de) Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs
ATE334682T1 (de) Verfahren zur herstellung von den trans-4-n- butylcyclohexanoicsaüre- und undecanoicsaüreestern von (7-alpha,11-beta)- dimethyl-17 beta -hydroxy-4-estren-3-one und deren medizynische anwendung
DE60008753D1 (de) Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen
DE602004022689D1 (de) Verwendung probiotischer bakterien zur behandlung von infektionen
ATE281841T1 (de) Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen
ATE414523T1 (de) Mechanisch verlängerte neuronale zellen und methoden zur herstellung und verwendung dieser zellen
ATE513471T1 (de) Verfahren und zusammensetzungen zur behandlung von erkrankungen
ATE334124T1 (de) Chinolinderivate, herstellungsprozess und verwendung zur behandlung von krankheiten, bei den s-cd23 involviert ist
TR200200278T2 (tr) Kalsilitik bileşimler
DE60111574D1 (de) Bisphosphonate-enthaltenden zusammensetzungen zur vorbeugung und/oder heilung von metabolischen knochenkrankheiten, verfahren zu ihren herstellung und benutzung dieser zusammensetzungen
DE50313329D1 (de) 1-phenyl-2-dimethylaminomethylcyclohexanverbindungen zur therapie von depressiven symptomatiken, schmerz und inkontinenz
ATE330596T1 (de) Verwendung von 3-bezoylphenylessigsäure-derivaten zur behandlung von netzhauterkrankungen
DE60039579D1 (de) Humane adulte astrozyten, sowie deren herstellung und verwendung
DE602004030661D1 (de) Verwendung von kahalalide verbindungen zur herstellung eines arzneimittels zur behandlung von psoriasis